Navigation Links
PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
Date:4/21/2010

MADRID, April 21 /PRNewswire/ -- PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

The AACR meeting is the leading convention on cancer research, bringing together more than 17,000 attendees each year and covering breakthroughs in oncology and basic, clinical and epidemiological research.

Two trials provided new data on Yondelis(R) (trabectedin), a marine-based anti-tumor drug currently produced by chemical synthesis. Yondelis(R) (trabectedin) has European Commission approval for advanced and metastatic soft tissue sarcoma (STS) and for recurrent platinum-sensitive ovarian cancer in combination with Doxil/Caelyx.

Various in vitro trials have shown that trabectedin's activity depends at least partly on the nucleotide excision repair (NER) mechanism. A new trial is evaluating if the status of ERCC5 (XPG), an endonuclease-3 that plays a key role in the excision of damaged DNA, is linked to trabectedin's clinical activity in patients with advanced soft tissue sarcoma.

New data suggests that overexpression of the wild-type ERCC5 gene may be a predictor of beneficial effects of trabectedin in patients with advanced STS.

A second trial is analyzing in vitro and in vivo activity of trabectedin in a group of 67 human tumors with a view to identify a common genetic profile and pinpoint Yondelis(R)-sensitive tumors. The results of this analysis demonstrate the viability of combining experimental trials with virtua
'/>"/>

SOURCE PharmaMar
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
3. Limbs for Life Foundation Presents the Roaring 20s at 9th Annual Benefit Gala and Auction
4. The Womens Heart Foundation Presents the Womens Heart Advocate Award for Medicine and Science to Multifunction CardioGram(TM) Inventor Dr. Joseph T. Shen
5. Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
6. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
7. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
8. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
9. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
10. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
11. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... DIEGO , July 24, 2014 ... industry leader in bioactive lipid-targeted therapeutics, reported interim ... where ASONEP™ is being investigated as a treatment ... that have failed at least one therapy involving ... no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), ...
(Date:7/24/2014)... N.J., July 24, 2014 , Revenues ... year , Adjusted diluted EPS from continuing operations of ... EPS from continuing operations of $0.92, 7% below prior year ... versus prior year , Full year 2014 revenues now ... to 4% previously , Full year 2014 adjusted diluted ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes ... sales increased 3% to $701 million.  Sales grew organically by ... percentage point to sales growth. , By business unit, ... and 1% in SAFC Commercial. , Reported diluted EPS ... of 13%.  Adjusted diluted EPS in Q2 2014 was also ...
Breaking Medicine Technology:Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12
... budget pressures, countries around the world are making ... lure the biopharmaceutical research sector away from the ... Technology Partnership Practice. The study, commissioned ... (PhRMA), further found that while many countries are ...
...   Accuray Incorporated (Nasdaq: ARAY ), ... of Richard Pettingill, LFACHE as a member of the ... Richard Pettingill,s career as a healthcare executive ... variety of prominent organizations. Most recently, Pettingill, who is ...
Cached Medicine Technology:New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 2New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 3Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 2Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 3
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... increases your risk of death, but recessions decrease ... While previous studies of individuals have shown that ... mortality rate, more comprehensive studies have shown, unexpectedly, ... increase. Researchers from Drexel University and the University ... better understand these seemingly contradictory findings. , Using ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 While healthcare ... in providing quality interpretation services to non-English speakers within ... down. According to Common Sense Advisory, the language ... to $2.3 billion in 2016 (1); additionally, officials at ... to shift over to video remote interpreting ...
(Date:7/24/2014)... known as neonicotinoids, were found commonly in streams ... study. This is the first broad-scale investigation of ... one of the first conducted within the United ... of insect pests, use of neonicotinoid insecticides has ... United States, particularly in the Midwest. The ...
(Date:7/24/2014)... Dr. Kwame Bawuah Edusei, a diplomat, entrepreneur, medical ... to the youth to persevere in their endeavors to ... the youth to stay away from social vices and ... will afford you the opportunity of acquiring life surviving ... in your career path.” Professionals in the fields of ...
Breaking Medicine News(10 mins):Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Joblessness could kill you, but recessions could be good for your health 2Health News:Joblessness could kill you, but recessions could be good for your health 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 2Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 4Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2
... aid in understanding ADD and more , FRIDAY, Aug. 28 ... a crowd, it appears that your "mind,s eye" acts like ... until you find the right person. , Researchers from the ... as they searched for a specific tilted, colored bar among ...
... 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... announced today that,the Beijing Public Health Bureau has selected ... Sinovac,s seasonal influenza vaccine, for,the benefit of the citizens ... process for the purchase of flu vaccines and,corresponding services ...
... , HARBIN, China, Aug. 28 ... Medical" or "the Company") (Nasdaq: CSKI ), ... People,s Republic of China ("PRC"), today announced that the,Company,s ... Thursday,September 24, 2009 at Harbin Shen Te Hotel which ...
... ... , ... (PRWEB) August 28, 2009 -- Promising cancer research treatment breakthrough seeks funding for corroboration., ... CHAI Foundation , a small 501(c)(3) non-profit medical research organization seeking to find ...
... , TOKYO, Aug. 28 ALOKA CO., ... generation of compact color ultrasound systems. This new multi-purpose system, ... fully upgradable and easy to use. , , ... ProSound Alpha 10 and Alpha 7, the ProSound Alpha 6 ...
... , TOSU, Saga, Japan and MIAMI, Aug. ... Inc. today announced the completion of their acquisition of Noven Pharmaceuticals, ... Inc., a wholly owned subsidiary of Hisamitsu U.S., Inc., with and ... the Agreement and Plan of Merger among the companies, at the ...
Cached Medicine News:Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 3Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 2Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 3Health News:Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 3Health News:Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals 2
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... Myeloperoxidase IgG ELISA test system is intended ... IgG-class antibody to myeloperoxidase in human serum. ... used as an aid in the diagnosis ... elevated levels of anti-neutrophil cytoplasmic antibodies (ANCA). ...
Medicine Products: